184: New-Onset Atrial Fibrillation in Patients With Septic Shock

Arnautovic, Jelena; Mazhar, Areej; Souther, Britni; Mikhjian, Gary; Huda, Najia

doi:10.1097/01.ccm.0000528203.26725.d6

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The patients underwent continuous monitoring using a three/five-lead monitor equipped with arrhythmia detection algorithms, alarms, and Holter recording capabilities throughout their ICU stay. The study revealed the development of NOAF in 29 patients (29%), with 22 patients (75.8%) experiencing a single occurrence and 7 patients (24.2%) encountering recurrent AF during their ICU stay [33]. This comprehensive monitoring approach, including Holter ECG, provides valuable insights into the occurrence and patterns of AF in the context of septic shock.…”

Section: Discussionmentioning

confidence: 96%

“…Moreover, NOAF has been linked to additional factors, including a lower ejection fraction (EF), advanced age, elevated levels of troponin-HS and NT-pro-BNP, and a prolonged QRS duration. Using an updated definition of septic shock, Rabie et al conducted a prospective study involving 100 septic shock patients, representing one of the largest series to date [33]. The patients underwent continuous monitoring using a three/five-lead monitor equipped with arrhythmia detection algorithms, alarms, and Holter recording capabilities throughout their ICU stay.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Landiolol for Treatment of New-Onset Atrial Fibrillation in Critical Care: A Systematic Review

Levy,

Slama,

Lakbar

et al. 2024

JCM

View full text Add to dashboard Cite

Background: new-onset atrial fibrillation remains a common complication in critical care settings, often necessitating treatment when the correction of triggers is insufficient to restore hemodynamics. The treatment strategy includes electric cardioversion in cases of hemodynamic instability and either rhythm control or rate control in the absence of instability. Landiolol, an ultrashort beta-blocker, effectively controls heart rate with the potential to regulate rhythm. Objectives This review aims to compare the efficacy of landiolol in controlling heart rate and converting to sinus rhythm in the critical care setting. Methods: We conducted a comprehensive review of the published literature from 2000 to 2022 describing the use of landiolol to treat atrial fibrillation in critical care settings, excluding both cardiac surgery and medical cardiac care settings. The primary outcome assessed was sinus conversion following landiolol treatment. Results: Our analysis identified 17 publications detailing the use of landiolol for the treatment of 324 critical care patients. While the quality of the data was generally low, primarily comprising non-comparative studies, landiolol consistently demonstrated similar efficacy in controlling heart rate and facilitating conversion to sinus rhythm in both non-surgical (75.7%) and surgical (70.1%) settings. The incidence of hypotension associated with landiolol use was 13%. Conclusions: The use of landiolol in critical care patients with new-onset atrial fibrillation exhibited comparable efficacy and tolerance in both non-surgical and surgical settings. Despite these promising results, further validation through randomized controlled trials is necessary.

show abstract

Section: Discussionmentioning

confidence: 96%

Section: Discussionmentioning

confidence: 99%